Mark R. Silvis
Huntsman Cancer Institute
20 Papers
31 Citations
Mark R. Silvis is an academic researcher from Huntsman Cancer Institute. The author has contributed to research in topics: Biology & Medicine. The author has an hindex of 14, co-authored 17 publications. Previous affiliations of Mark R. Silvis include University of Utah & Fred Hutchinson Cancer Research Center.
Chat about Author
Papers
α-Catenin Is a Tumor Suppressor That Controls Cell Accumulation by Regulating the Localization and Activity of the Transcriptional Coactivator Yap1
Mark R. Silvis,Bridget T. Kreger,Wen-Hui Lien,Olga Klezovitch,G. Marianna Rudakova,Fernando D. Camargo,Dan M. Lantz,John T. Seykora,Valeri Vasioukhin,Valeri Vasioukhin +9 more
TL;DR: This work shows that deletion of αE (α epithelial) catenin in the hair follicle stem cell compartment resulted in the development of skin squamous cell carcinoma in mice, and identifies αE-catenin as a tumor suppressor that inhibits Yap1 activity and sequesters it in the cytoplasm.
355
αE-catenin inhibits a Src–YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway
TL;DR: It is demonstrated that the tumor suppressor function of αE-catenin involves negative regulation of the β4 integrin-SRC signaling pathway and that SRC-mediated phosphorylation and activation of YAP1 are an alternative to the canonical Hippo signaling pathway that directly connect oncogenic tyrosine kinase signaling with YAP 1.
Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma
Yong Yu,Kolja Schleich,Bin Yue,Sujuan Ji,Philipp Lohneis,Kristel Kemper,Mark R. Silvis,Nouar Qutob,Ellen van Rooijen,Ellen van Rooijen,Melanie Werner-Klein,Lianjie Li,Dhriti Dhawan,Svenja Meierjohann,Maurice Reimann,Abdel G. Elkahloun,Steffi Treitschke,Bernd Dörken,Bernd Dörken,Christian Speck,Frédérick A. Mallette,Leonard I. Zon,Leonard I. Zon,Sheri L. Holmen,Daniel S. Peeper,Yardena Samuels,Clemens A. Schmitt,Clemens A. Schmitt,Soyoung Lee,Soyoung Lee +29 more
TL;DR: A large subset of established melanoma cell lines and primary human melanoma samples presented with a collective upregulation of related and unrelated H3K9 demethylase activities, whose targeted inhibition restored senescence, even in Braf inhibitor-resistant melanomas, evoked secondary immune effects and controlled tumor growth in vivo.
152
Mutant IDH1 Promotes Glioma Formation In Vivo
Beatrice Philip,Beatrice Philip,Diana X. Yu,Diana X. Yu,Mark R. Silvis,Mark R. Silvis,Clifford Shin,Clifford Shin,James P. Robinson,Gemma L. Robinson,Gemma L. Robinson,Adam E. Welker,Stephanie N. Angel,Stephanie N. Angel,Sheryl R. Tripp,Joshua A. Sonnen,Joshua A. Sonnen,Matthew W. VanBrocklin,Matthew W. VanBrocklin,Richard J. Gibbons,Ryan E. Looper,Howard Colman,Howard Colman,Sheri L. Holmen,Sheri L. Holmen +24 more
TL;DR: Although not sufficient on its own, IDH1R132H cooperated with PDGFA and loss of Cdkn2a, Atrx, and Pten to promote glioma development in vivo, and these tumors resembled pro-neural human mutant IDH 1 GBM genetically, histologically, and functionally.
108
Melanoma Brain Metastasis: Mechanisms, Models, and Medicine
TL;DR: An overview of newly discovered mechanisms of melanoma spread to the brain is provided, preclinical models that are being used to further the understanding of this deadly disease are discussed and an update of the current clinical trials for melanoma patients with brain metastases is provided.
60